More than one-fourth of all top-10 pharma TV spending in July came from one brand—AbbVie's Humira. The immunology blockbuster brand dropped $42.5 million on TV ads, well ahead of Gilead Sciences’ Truvada, which was the nearest competitor at $19.7 million, according to data from real-time TV ad tracker iSpot.tv.

But does that mean TV media dipped among the rest of the pharma companies, or that AbbVie ramped up spending on Humira? Maybe a bit of both. Summer months tend to see lower spending on TV buys in general as people spend more time outdoors and not inside glued to the tube.

On the other hand, AbbVie also may be trying to wring all it can from its 15-year-old immunology blockbuster, with generic competition already on the market in Europe. The brand posted its first-ever dip in global sales in the first quarter of 2019, with total sales slipping 5.6% to $4.46 billion. However, in the U.S., which won’t see generic competition until 2023, sales were up 7% to $3.22 billion. AbbVie has been spending on TV ads well above last year's level, with a total $277 million through the first seven months compared with $219 million over the same period last year. 

Meanwhile, another multi-indication immunology med, Novartis' Cosentyx, is back on the top-10 list for the first time since last year. It ran three commercials in July—two for both psoriasis and psoriatic arthritis and the third only for psoriasis in Novartis' long-running campaign with singer Cyndi Lauper.

Eli Lilly's Emgality stayed on the list for the sixth month in a row since its ad launched, aided by the mid-July debut of a new TV ad with female friends enjoining a garden party and not having to imagine migraine-free days. The new spot joins the longer-running mother and daughter imagination play date ad where the two pretend to be pirates and other characters.

Overall, pharma TV spending among the top 10 in July topped $144 million, up slightly from $140 million in June but still down from $177 million in May and $168 million in April.